Share This Page
Patent: 7,429,387
✉ Email this page to a colleague
Summary for Patent: 7,429,387
| Title: | Use of botulinum toxin therapy for treatment of recalcitrant voiding dysfunction | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Abstract: | The present invention related to methods for treating neurological-urological conditions. This is accomplished by administration of at least one neurotoxin. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventor(s): | Schmidt; Richard A. (Arvada, CO) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assignee: | The Regents of the University of Colorado (Boulder, CO) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Application Number: | 11/077,895 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent Claims: | see list of patent claims | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Patent landscape, scope, and claims summary: | US Patent 7,429,387: Claims, Expiration, Orange Book Status, and Competitive Patent LandscapeUS Patent 7,429,387 covered injection of botulinum toxin into the lateral bladder wall to treat recalcitrant voiding dysfunction. The patent was assigned to Allergan, now part of AbbVie, and expired on November 25, 2023, based on its 20-year term from the earliest nonprovisional filing date. Its principal commercial relevance was the use of botulinum toxin type A, including Botox, for bladder dysfunction and urinary incontinence. The patent no longer creates an enforceable U.S. exclusion right for new acts of infringement. Its historical scope remains relevant to pre-expiration damages, Orange Book analysis, freedom-to-operate reviews covering earlier conduct, and the development of follow-on botulinum toxin products. What does US Patent 7,429,387 cover?US 7,429,387 covers a treatment method with four core elements:
The patent contains two independent method claims:
Dependent claims add patient type, symptoms, toxin type and dose limitations. The provided claim text contains apparent transcription errors. Claim 2 reads "wherein the patent is a human," but the legally coherent limitation is "wherein the patient is a human." Claim 7 also appears to omit "of" before "a patient." Claim construction must rely on the issued patent, prosecution history and certified patent records, not an OCR or database transcription. When did US Patent 7,429,387 expire?The patent was granted on September 30, 2008. Its earliest claimed nonprovisional priority or filing date was November 25, 2002, and its ordinary 20-year patent term ended on November 25, 2023, subject to any applicable patent-term adjustment reflected in the official USPTO record.[1]
An expired patent cannot support a new U.S. infringement injunction or continuing royalty obligation solely on the basis of the expired claims. Historical infringement before expiration may remain relevant if a timely claim was preserved and the applicable damages requirements are satisfied. What are the independent claims of US 7,429,387?Claim 1: broad botulinum toxin bladder-wall treatmentClaim 1 is the broadest independent claim. It does not limit the toxin to type A, Botox, a particular formulation or a specified dose. Its principal limitations are the injection site and the clinical condition. The claim potentially reaches treatment using:
The key narrowing term is "lateral bladder wall." An injection into another bladder region, such as the trigone, bladder neck or detrusor muscle without satisfying the lateral-wall limitation, would raise a claim-construction issue. Claim 7: type A and therapeutic amountClaim 7 is narrower because it requires botulinum toxin type A and a therapeutically effective amount. Claims 8 through 11 further define dose ranges or dose amounts:
Claims 10 and 11 are species claims directed to 200 IU and 400 IU administrations. Claim 9 is a weight-based range. These claims would have been most relevant to clinical protocols using fixed doses or patient-weight-based dosing. How strong were the patent claims?The patent had meaningful historical value because it combined a specific anatomical injection site with a therapeutic indication that became commercially important. Its strongest features were:
The main vulnerabilities were claim construction, prior art and written-description support. Claim construction risk"Recalcitrant voiding dysfunction" is a clinical descriptor rather than a precise disease code. Its meaning would likely depend on the specification and prosecution history. The term could be argued to require treatment-resistant, persistent or otherwise difficult-to-treat dysfunction. A product or physician treating routine overactive bladder could dispute whether the condition was "recalcitrant." "Lateral bladder wall" also creates a factual boundary. A procedure that injects multiple bladder regions may or may not satisfy the limitation depending on whether at least one injection reaches the claimed lateral wall and how the claim is construed. Prior-art riskThe patent's validity would have turned on whether earlier references disclosed or made obvious:
The dosing claims would not necessarily survive merely because the parent method claim survived. A prior-art reference disclosing bladder injections could create a separate obviousness argument against the 200 IU, 400 IU or weight-based limitations. Enablement and written-description riskThe broadest claim covers botulinum toxin generally, while dependent claim 5 specifies type A. The specification would need to support the full breadth of the generic botulinum toxin claim, including the disclosed serotypes, formulations, administration methods and clinical outcomes. A challenger could argue that data limited to type A did not support every botulinum toxin species or every recalcitrant voiding dysfunction. Because the patent has expired, these issues now have limited effect on prospective market entry. They remain relevant to historical litigation and damages analysis. What was the FDA and Orange Book status?Botox was approved by FDA under NDA 103000 for multiple indications. FDA later approved Botox for:
The FDA-approved bladder label specifies injection into the detrusor muscle through cystoscopy. The label includes distinct dosing for overactive bladder and neurogenic detrusor overactivity, with 100-unit and 200-unit regimens, respectively.[2] US 7,429,387 was part of the historical patent landscape associated with Allergan's bladder-use strategy and has been identified in public drug-patent databases in connection with Botox-related use protection. Orange Book listing status must be evaluated by NDA, use code and the applicable annual Orange Book record because listing status can change after patent expiration.[3] The patent did not independently create FDA approval. FDA approval depended on clinical evidence, manufacturing controls, labeling and safety data. Conversely, FDA approval did not establish that every labeled use infringed every claim of the patent. Patent scope and regulatory labeling are separate analyses. What formulations are protected by US 7,429,387?The patent claims are primarily method claims. They do not appear, based on the quoted claims, to claim:
The claims could nevertheless cover use of different formulations if the formulation is administered by injecting botulinum toxin into the lateral bladder wall and satisfies the remaining claim elements. Separate formulation and manufacturing patents may have protected Botox's composition, stability, purification or production process. Those rights are distinct from the expired bladder-treatment claims. A formulation patent could create an independent risk even if a bladder-use patent has expired. What dose ranges did the patent protect?The patent's dosing claims are unusually important because they overlap with clinically relevant bladder-treatment regimens.
Unit comparisons require caution. Botulinum toxin potency units are product-specific and are not interchangeable across manufacturers. FDA labeling warns that potency units for Botox are not comparable with units used for other botulinum toxin products.[2] A competitor cannot assume that 200 units of another product is pharmacologically or legally identical to 200 units of Botox. Which companies challenged or competed with the patent?No broad, sustained U.S. Paragraph IV challenge to this specific expired patent is necessary for current market entry. The patent expired before a generic or biosimilar challenger would need to defeat it to launch a competing bladder treatment. The relevant competitive companies and products included:
The principal commercial competition has come from oral antimuscarinics, beta-3 adrenergic agonists, sacral neuromodulation, percutaneous tibial nerve stimulation and catheter-based management. Those alternatives do not generally raise infringement issues under US 7,429,387 because they do not involve the claimed botulinum toxin injection method. What generic launch risks existed before expiration?Before November 25, 2023, a generic or follow-on product faced several potential risks:
After expiration, the primary patent risk shifted to unexpired formulation, manufacturing, device, process or separate method-of-use patents. How does US 7,429,387 compare with later Botox bladder patents?US 7,429,387 is best characterized as an early foundational use patent. Later patents and patent applications in the Botox estate could target:
The expiration date of each later patent must be calculated independently. A continuation does not automatically receive a new 20-year term. Continuation claims generally retain the parent application's term framework, although patent-term adjustment, terminal disclaimers and priority-chain details can affect the operative date. Is there biosimilar risk for Botox?Botox is a biologic-like complex protein product with clinically important manufacturing and potency characteristics. A competing botulinum toxin product could pursue an FDA pathway different from a conventional small-molecule ANDA, depending on the product's regulatory classification and reference-product strategy. The expired patent reduces one barrier to entry, but it does not eliminate:
Botulinum toxin products are not automatically interchangeable merely because they share a serotype. FDA has repeatedly treated potency units as product-specific in labeling.[2] What patent litigation affects US 7,429,387?The patent's current litigation significance is limited by expiration. Publicly available patent records identify the patent as an Allergan botulinum toxin use patent, but the quoted claim set alone does not establish a complete litigation history, including every Paragraph IV notice, settlement agreement, district-court action or appeal. There is no basis to treat the patent as currently enforceable against a new U.S. bladder-treatment protocol. Any historical litigation review must distinguish:
Key Takeaways
FAQs About US Patent 7,429,387Does US 7,429,387 still block Botox bladder injections?No. The patent expired on November 25, 2023. It no longer creates a prospective U.S. patent barrier to Botox bladder injections. Did US 7,429,387 cover overactive bladder?Potentially, if the condition qualified as a recalcitrant voiding dysfunction and the injection was made into the lateral bladder wall. The patent did not use the modern FDA indication language as its sole limitation. Did the patent cover 100 units of Botox?The quoted claims expressly identify 200 IU and 400 IU, not 100 IU. A 100-unit procedure could still fall within claim 1 or claim 7 if the remaining limitations were met, because those independent claims do not require 200 or 400 units. Are Dysport, Xeomin and Botox units legally interchangeable under this patent?No. Botulinum toxin potency units are product-specific. The products may compete clinically, but their units and labeling cannot be treated as equivalent without product-specific analysis. Can a company launch a competing bladder botulinum toxin product after patent expiration?Patent expiration removes the specific barrier created by US 7,429,387. Launch risk still depends on FDA pathway, manufacturing capability, clinical evidence, product labeling and any other unexpired patents covering formulation, production, delivery or treatment protocols. References
More… ↓ |
Details for Patent 7,429,387
| Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
|---|---|---|---|---|---|---|---|
| Abbvie Inc. | BOTOX COSMETIC | onabotulinumtoxina | For Injection | 103000 | 9-Dec-91 | 7,429,387 | 2025-03-11 |
| Abbvie Inc. | BOTOX | onabotulinumtoxina | For Injection | 103000 | 9-Dec-91 | 7,429,387 | 2025-03-11 |
| >Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
International Patent Family for US Patent 7,429,387
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| World Intellectual Property Organization (WIPO) | 9903483 | ⤷ Start Trial |
| United States of America | 2002025327 | ⤷ Start Trial |
| United States of America | 2004126380 | ⤷ Start Trial |
| United States of America | 2004180065 | ⤷ Start Trial |
| United States of America | 2004259788 | ⤷ Start Trial |
| United States of America | 2005048084 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
